Shifang Yuan1, Changhong Shi, Rui Ling, Ting Wang, Hui Wang, Wei Han. 1. Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, 17 Changle West Road, Xi'an, 710033, People's Republic of China.
Abstract
PURPOSE: Mucin-1 (MUC1) is a breast tumor-associated antigen. However, clinical trials with MUC1 showed that, with respect to its expression levels, MUC1 is a relatively poor immunogen in human beings. Evidence showed that MUC1-specific immunodominant B and T cell epitopes are derived from the variable-number tandem repeat (VNTR) region. Therefore, immunotherapy that targets multiple VNTRs may induce anti-MUC1 immune responses. GM-CSF has been shown to increase the percentage and activity of antigen-presenting cells. In this study, we constructed two recombinant Bacillus Calmette-Guérin (BCG) vaccines that combine the expression of multiple tandem repeats of MUC1 and CSF. The effect of two novel breast cancer vaccines (rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF) on the growth of breast tumor on hu-PBL-SCID mice was evaluated. METHODS: We coupled VNTRs (4 and 8) of MUC1 with GM-CSF (MVNTR4-CSF and MVNTR8-CSF). The MVNTR4-CSF and MVNTR8-CSF were inserted into the pDE22 plasmid and transformed into competent BCG by electroporation. The effect of both BCG vaccines on the growth of breast tumor on hu-PBL-SCID mice was evaluated. RESULTS: The growth of MUC1-positive breast tumors from hu-PBL-SCID mice immunized with two vaccines was significantly inhibited. CONCLUSIONS: rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF vaccines may be good candidates for breast tumor immunotherapy.
PURPOSE: Mucin-1 (MUC1) is a breast tumor-associated antigen. However, clinical trials with MUC1 showed that, with respect to its expression levels, MUC1 is a relatively poor immunogen in human beings. Evidence showed that MUC1-specific immunodominant B and T cell epitopes are derived from the variable-number tandem repeat (VNTR) region. Therefore, immunotherapy that targets multiple VNTRs may induce anti-MUC1 immune responses. GM-CSF has been shown to increase the percentage and activity of antigen-presenting cells. In this study, we constructed two recombinant Bacillus Calmette-Guérin (BCG) vaccines that combine the expression of multiple tandem repeats of MUC1 and CSF. The effect of two novel breast cancer vaccines (rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF) on the growth of breast tumor on hu-PBL-SCID mice was evaluated. METHODS: We coupled VNTRs (4 and 8) of MUC1 with GM-CSF (MVNTR4-CSF and MVNTR8-CSF). The MVNTR4-CSF and MVNTR8-CSF were inserted into the pDE22 plasmid and transformed into competent BCG by electroporation. The effect of both BCG vaccines on the growth of breast tumor on hu-PBL-SCID mice was evaluated. RESULTS: The growth of MUC1-positive breast tumors from hu-PBL-SCID mice immunized with two vaccines was significantly inhibited. CONCLUSIONS: rBCG-MVNTR4-CSF and rBCG-MVNTR8-CSF vaccines may be good candidates for breast tumor immunotherapy.
Authors: R G Barletta; B Snapper; J D Cirillo; N D Connell; D D Kim; W R Jacobs; B R Bloom Journal: Res Microbiol Date: 1990 Sep-Oct Impact factor: 3.992
Authors: Karl G Kohlgraf; Andrew J Gawron; Michiyo Higashi; Michelle L VanLith; XiaoLing Shen; Thomas C Caffrey; Judy M Anderson; Michael A Hollingsworth Journal: Cancer Immunol Immunother Date: 2004-12 Impact factor: 6.968
Authors: Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn Journal: Cancer Immunol Immunother Date: 2004-09-14 Impact factor: 6.968
Authors: Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Heleni Drakaki; Bruce E Loveland; Sara J Piddlesden; Magdalena Plebanski; Dodie S Pouniotis; Michael N Alexis; Ian F McKenzie; Stamatis Vassilaros Journal: Breast Cancer Res Date: 2006-06-15 Impact factor: 6.466